The pharma giant recently announced a partnership with the Professional Pickleball Association (PPA) to help raise awareness for its eosinophilic asthma biologic Fasenra. The collaboration is a ...

NICE has recommended in a draft decision that AstraZeneca’s latest lung drug Fasenra can be funded by the NHS in severe asthma – but only in patients that are ineligible for GlaxoSmithKline ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer (NSCLC), the British pharma has rolled out early data from a trial ...

This episode of the pharmaphorum podcast focuses on lung cancer, with AstraZeneca’s VP, global franchise head, Tagrisso TDR (Tumour Drivers and Resistance) Patrick Connor explaining why the ...

WILMINGTON, DE — AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its role as a backbone therapy across treatment stages ...

Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate the blockbuster market for lung cancer treatment, but data from a forthcoming study could quickly shake up the ...

where market competition is already fierce The market leader in lung cancer drugs, AstraZeneca, declined to comment without seeing more detailed clinical data about the Chinese product A victory ...

AstraZeneca presented new data at the European Lung Cancer Congress (ELCC) 2025, demonstrating the potential of artificial intelligence (AI) in improving lung cancer risk detection, especially within ...

The European Commission also approved AstraZeneca's Imfinzi (durvalumab) in combination with chemotherapy for adults with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence ...

(Alliance News) - AstraZeneca PLC on Tuesday reported positive new study results for its lung cancer drug Tagrisso, strengthening its position as a "backbone" treatment for patients with EGFR ...

This approval is based on a press release statement and adds to AstraZeneca’s growing portfolio in the lung cancer segment, as the company continues to focus on innovative treatments that could ...